Data from EMC - Curated by Toby Galbraith - Last updated 14 March 2017

Licensing authority

MHRA (Medicines and Healthcare products Regulatory Agency, UK)

Indication(s)

Actikerall is indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients.

Grade I/II intensity is based on the 4-point scale of Olsen et al. (1991).

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

Visit Prostate Cancer

More information

Category Value
Authorisation number PL 33016/0015
Orphan designation No
Date First Approved 03-06-2011
Type POM
Marketing authorisation holder Almirall Hermal GmbH

Related Content